Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V. and other illnesses.
Chinese Company Under Congressional Scrutiny Makes Key U.S. Drugs
Latest:
US bill to restrict WuXi AppTec, Chinese biotechs revised to give more time to cut ties
Ms. Cat’s Chronicles 